Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk announced today the
results from two Ozempic® (once-weekly semaglutide 1.0 mg)
head-to-head Phase 3 clinical trials, SUSTAIN 8 and SUSTAIN 10, which
* Ozempic® was superior to treatment with the SGLT-2 inhibitor
canagliflozin (300 mg) in reducing HbA1c and body weight in
with type 2 diabetes uncontrolled on metformin.1
* Ozempic® was superior to Victoza® (liraglutide 1.2 mg) in
HbA1c and body weight in people with type 2 diabetes.2
These data were presented at the European Association for the Study
of Diabetes (EASD) Annual Meeting in Barcelona, and simultaneously
published in The Lancet Diabetes & Endocrinology (SUSTAIN 8) and
Diabetes and Metabolism (SUSTAIN 10).1,2
"We are proud of the superior clinical profile of once-weekly
Ozempic®, as demonstrated through all the SUSTAIN clinical trials,
and encouraged by these new data which further reinforce the value of
Ozempic® for people with type 2 diabetes," said Mads Krogsgaard
Thomsen, executive vice president and chief science officer of Novo
These trials form part of the extensive SUSTAIN programme, a global
clinical development programme that comprises more than 10 Phase 3
trials involving more than 10,065 adults with type 2 diabetes. To
date, outcomes of SUSTAIN 1-7 and 9 have been published demonstrating
Ozempic® is a best-in-class, efficacious and well-tolerated treatment
option for people with type 2 diabetes.
At 52 weeks, Ozempic® demonstrated a superior reduction in mean HbA1c
of 1.5% compared to canagliflozin at 1.0%, from a baseline of 8.3%.
In addition, 66.1% of people treated with Ozempic® achieved HbA1c
treatment target <7% vs 45.1% of those treated with canagliflozin.
People treated with Ozempic® also demonstrated superior reductions in
body weight compared with canagliflozin with 5.3 kg vs 4.2 kg,
respectively, from a mean baseline of 90.2 kg. Significantly more
people treated with Ozempic® achieved reduction in body weight of
>=10% vs canagliflozin (22.3% vs 8.9%, respectively).
"To date, head-to-head trials of GLP-1 receptor agonists and SGLT-2
inhibitors have been limited," said Dr Ildiko Lingvay, University of
Texas Southwestern Medical Centre, Dallas, and lead study
investigator. "These data seen in the SUSTAIN 8 trial support
Ozempic® as an efficacious treatment option for reducing blood sugar
and body weight for people with type 2 diabetes after metformin."
At 30 weeks, Ozempic® demonstrated a superior reduction in mean HbA1c
compared to Victoza® (1.7% vs 1.0% respectively), from a mean
baseline of 8.2%. In addition, 80% of people treated with Ozempic®
achieved HbA1c treatment target of <7% vs 46% of those treated with
Victoza®. People treated with Ozempic® also demonstrated superior
reductions in body weight compared with Victoza® with 5.8 kg vs 1.9
kg, respectively, from a mean baseline of 96.9 kg. Significantly more
people treated with Ozempic® achieved reduction in body weight of
>=10% than those treated with Victoza® (19% vs 4%, respectively).
"Intensifying treatment with Ozempic® showed significant benefits
over Victoza® in terms of blood sugar control and reduction in body
weight, providing an alternative treatment option for those
uncontrolled on current treatment," said Dr Matthew Capehorn,
Rotherham Institute for Obesity, UK, and lead study investigator.
The tolerability of once-weekly Ozempic® was generally similar to
that of Victoza® and canagliflozin, except for higher rates of
gastrointestinal adverse events (AEs) with Ozempic® vs Victoza® and
more frequent infections and infestations with canagliflozin vs
Ozempic®. The safety profile of Ozempic® 1.0 mg in both trials was
consistent with the overall SUSTAIN clinical trial programme.
Once-weekly Ozempic® (semaglutide) is an analogue of human
glucagon-like peptide-1 (GLP-1) indicated as an adjunct to diet and
exercise to improve glycaemic control in adults with type 2
diabetes.3,4 Ozempic® was first approved by the US FDA in 2017 and is
now launched in 25 countries.
About SUSTAIN 8
SUSTAIN 8 is a 52-week double-blinded Phase 3 trial investigating the
efficacy and safety of once-weekly Ozempic® (semaglutide 1.0 mg) vs
canagliflozin 300 mg as add-on to metformin in people with type 2
diabetes. The primary endpoint was change in HbA1c from baseline to
Week 52, and key secondary endpoints include change in body weight at
Week 52 and proportion of people achieving HbA1c <7.0% (53 mmol/mol)
at Week 52.1
About SUSTAIN 10
SUSTAIN 10 is a 30-week open-label Phase 3b trial investigating the
safety and efficacy of Ozempic® 1.0 mg once-weekly vs Victoza® 1.2 mg
once-daily, as add-on to 1-3 oral antidiabetics (OADs) in 577 adults
with type 2 diabetes in Europe. The primary endpoint was change in
HbA1c at Week 30, and key secondary endpoints include change in body
weight at Week 30 and proportion of people achieving HbA1c <7.0% (53
mmol/mol) at Week 30.2
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 95 years
of innovation and leadership in diabetes care. This heritage has
given us experience and capabilities that also enable us to help
people defeat obesity, haemophilia, growth disorders and other
serious chronic diseases. Headquartered in Denmark, Novo Nordisk
employs approximately 41,600 people in 80 countries and markets its
products in more than 170 countries. For more information, visit
novonordisk.com , Facebook , Twitter , LinkedIn , YouTube .
1. Lingvay I, et al. Efficacy and safety of once-weekly semaglutide
versus daily canagliflozin as add-on to metformin in patients
type 2 diabetes (SUSTAIN 8): a double-blind, randomised,
controlled trial. The Lancet Diabetes & Endocrinology. Published
Online 17 September 2019. http://dx.doi.org/10.1016/PII
2. Capehorn MS, et al. Efficacy and safety of once-weekly
semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to
1-3 oral antidiabetic drugs in subjects with type 2 diabetes
(SUSTAIN 10). Diabetes Metab (2019).
3. EMA. Ozempic® Summary of Product Characteristics. Available at:
Last accessed: September 2019.
4. FDA. Ozempic® US Prescribing Information. December 2017.
Available at: http://www.novo-pi.com/ozempic.pdf
Mette Kruse Danielsen +45 3079 3883
Ken Inchausti (US) +1 609 240 9429
Peter Hugreffe Ankersen +45 3075 9085
Kristoffer Due Berg (US) +1 609 235 2989
Valdemar Borum Svarrer +45 3079 0301
Ann Søndermølle Rendbæk +45 3075 2253
Digital press kit: http://www.ots.at/pressemappe/PR57206/aom
Aktien auf dem Radar:Marinomed Biotech, Mayr-Melnhof, Addiko Bank, Kapsch TrafficCom, Telekom Austria, Agrana, ATX, ATX Prime, voestalpine, Bawag, Andritz, Strabag, Semperit, Zumtobel, FACC, Flughafen Wien, Frequentis, OMV, RBI, SW Umwelttechnik, Wienerberger, Amag, AMS, CA Immo, Immofinanz, Josef Manner & Comp. AG, Porr, Wolftank-Adisa Holding AG.
Die FACC ist führend in der Entwicklung und Produktion von Komponenten und Systemen aus Composite-Materialien. Die FACC Leichtbaulösungen sorgen in Verkehrs-, Fracht-, Businessflugzeugen und Hubschraubern für Sicherheit und Gewichtsersparnis, aber auch Schallreduktion. Zu den Kunden zählen u.a. wichtige Flugzeug- und Triebwerkshersteller.
>> Besuchen Sie 55 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER